HUIYU PHARMACEUTICAL and its subsidiaries have obtained overseas listing licenses for multiple products
I'm LongbridgeAI, I can summarize articles.
HUIYU PHARMACEUTICAL and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently obtained overseas marketing approvals for multiple products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, approved by the drug regulatory authorities of Denmark, Germany, Uzbekistan, and Bangladesh, respectively
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments